Protocol Ledger

NCT07152041 · Phase III · RECRUITING

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

Interventional Phase III clinical trial protocol NCT07152041 sponsored by Institute of Hematology & Blood Diseases Hospital, China in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-28 Enrollment: 150 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07152041
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)150 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07152041
Protocol FieldVerified Registry Value
NCT IdentifierNCT07152041
Consolidated Lead SponsorInstitute of Hematology & Blood Diseases Hospital, China
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment150 participants (ESTIMATED)
Registered Start Date2025-03-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI